（文章来源：每日经济新闻） 每经AI快讯，1月26日，生物医药概念午后快速拉升，凯普生物直线涨停，沃森生物、圣湘生物、万泽 股份、智飞生物、君实生物跟涨。 ...

Core Insights - The 2025 GDP forecast for China's top ten cities reveals a competitive landscape, with Shanghai and Beijing maintaining their positions as economic powerhouses, while cities like Shenzhen, Chongqing, and Guangzhou are rapidly advancing [1][3]. Group 1: Shanghai and Beijing - Shanghai's GDP is projected to reach 5.67 trillion yuan, an increase of 278.2 billion yuan from the previous year, with significant contributions from the Zhangjiang Science City and Yangshan Port, which has been the world's busiest container port for 19 consecutive years [1][5]. - Beijing's GDP is expected to surpass 5.2 trillion yuan, growing by 388 billion yuan, driven by a surge in tech startups in Zhongguancun and a digital economy that constitutes over 65% of its GDP [3][5]. Group 2: Emerging Cities - Shenzhen's GDP is forecasted to hit 3.89 trillion yuan, with a growth rate of 5.68%, bolstered by major players like BYD in the electric vehicle market, which holds a 12% global share [5][7]. - Chongqing's GDP is anticipated to reach 3.37 trillion yuan, with a notable contribution from the automotive sector, where companies like Changan and Seres account for 12% of its GDP [7]. - Guangzhou's GDP is projected at 3.23 trillion yuan, supported by investments in AI and digital economy sectors, with local companies contributing significantly to national testing mileage in smart vehicles [7]. Group 3: Other Notable Cities - Suzhou's GDP is expected to be 2.79 trillion yuan, with a strong focus on nanotechnology and a 20% annual growth in patents in biomedicine and integrated circuits [7]. - Chengdu is set to achieve a GDP of 2.5 trillion yuan, with a remarkable growth rate of 6.57%, driven by advancements in electronic information and new energy industries [8]. - Hangzhou's GDP is forecasted at 2.3 trillion yuan, with its digital economy core industries accounting for over 30% of its GDP, showcasing a transition from an e-commerce hub to a smart city [8]. - Wuhan's GDP is projected to reach 2.23 trillion yuan, with significant contributions from the optoelectronic information industry and a resilient economic recovery post-pandemic [8]. - Nanjing's GDP is expected to be 1.93 trillion yuan, with high-tech industries like integrated circuits and new energy vehicles making up over 55% of its GDP [9].

Core Insights - Junshi Biosciences is a leading biopharmaceutical company focused on innovation, with a mission to provide world-class, trustworthy innovative drugs to patients globally [1] - The company has developed over 50 innovative drugs, with 5 products already launched in domestic and international markets, including the first domestically developed PD-1 inhibitor, Toripalimab [1] Group 1: Digital Transformation and Innovation - The company has implemented a digital control system at its Shanghai Lingang production base, which is recognized as a model for modern biopharmaceutical industrialization [1] - The project includes the establishment of an Electronic Batch Record (EBR) system, which automates data collection and enhances compliance, efficiency, and supply chain stability [1] - The system features 1780 standardized operational steps and 4380 monitoring points for anomalies, significantly improving the efficiency of batch record review and release [1] Group 2: Industry Impact and Future Directions - The project serves as a replicable and promotable model for digital transformation in the biopharmaceutical industry [2] - Junshi Biosciences aims to continue deepening its digital and intelligent transformation to enhance production efficiency and product quality, ultimately providing safer and more accessible innovative drugs to global patients [2]

Group 1 - The core viewpoint of the news highlights the strong performance of the pharmaceutical and medical services sectors, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index rising by 1.52% as of 11:05 AM on January 23, 2026, driven by significant gains in stocks such as Chengdu Xian Dao (+5.48%) and BGI Genomics (+4.25%) [1] - The Ministry of Commerce and eight other departments have issued opinions to promote high-quality development in the drug retail industry, encouraging retail enterprises to participate in centralized drug procurement and to enhance their bargaining power through joint purchasing [1] - The Chinese pharmaceutical industry is at a pivotal point for global value reassessment, with 2026 being a critical year to validate transformation outcomes, as highlighted by CITIC Securities [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [2] - The CSI Innovation Medicine ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index, providing an easy investment option for those without stock accounts through the linked fund [3]

消息面上，商务部等九部门发布关于促进药品零售行业高质量发展的意见提出，优化药品营销体系。倡 导医药生产企业与全国或区域大型医药流通企业深度合作，以市场为导向规范药品购、销价格体系，促 进药品零售行业跨省、跨地区公平竞争，引导零售药品价格保持合理水平。鼓励创新药、参比制剂等药 品进零售药店销售渠道。鼓励医药电商平台开放数据接口，加强线上、线下药品零售价与省级医药采购 平台挂网价的联动监测，加强定点药店医保药品量价比较指数和药品比价小程序的推广应用。 江海证券表示，我们认为随着全球生物医药投融资环境逐步回暖，中国创新药企业出海已成为核心发展 趋势。新年首周，国内创新药领域便落地5项对外授权合作，涵盖小分子抑制剂、单抗、双抗、ADC和 RDC等多个技术领域，充分展现了中国在生物医药各技术领域的全球领先布局实力。 （文章来源：21世纪经济报道） 1月23日，A股三大指数集体上涨，中证创新药产业指数截至发稿上涨1.37%，该指数成分股中，昭衍新 药上涨超5%，贝达药业、君实生物-U、荣昌生物、泰格医药、沃森生物等跟涨。 相关ETF方面，创新药ETF（159992）截至发稿涨1.17%，成交额超1.5亿元，盘中交投活跃。 ...

Core Viewpoint - The A-share market experienced fluctuations on January 22, with the Shanghai Composite Index rising by 0.14%. The innovative drug sector faced pressure, as evidenced by the decline of the Science and Technology Innovation Drug ETF Huatai (589120) by 1.51% by 15:00. However, the ETF saw a net inflow of funds totaling 27.7361 million yuan over the past three days, indicating a trend of buying on dips [1]. Group 1: Market Performance - The Science and Technology Innovation Drug ETF Huatai (589120) recorded a net inflow of 27.7361 million yuan over three days, showing a clear trend of increased buying despite market declines [1]. - By 15:00, the ETF's component stocks exhibited mixed performance, with notable gains from Kangxinuo at 1.81%, Baiaotai at 0.49%, and Haoyuan Pharmaceutical at 0.48%. Conversely, Yifang Bio fell over 6%, Rongchang Bio dropped over 4%, and Baili Tianheng decreased by over 3% [6]. Group 2: Industry Insights - According to the National Medical Insurance Administration, 76 innovative drugs are expected to be approved for market entry by the National Medical Products Administration by 2025, marking a record high and indicating a trend towards diversified innovative therapies in China [4]. - Donghai Securities predicts that the innovative drug sector is entering a new era, transitioning from a generics-dominated market (pre-2018) to a period of transformation (2018-2025) characterized by price reductions and increased R&D investments in innovative drugs. By 2026, innovative drugs are expected to dominate the pharmaceutical industry in China, supported by complementary insurance policies and a focus on the pace of new drug launches and competitive dynamics [5].

Policy Developments - The National Medical Products Administration (NMPA) held a meeting to promote the boron neutron capture therapy system, emphasizing the need for enhanced coordination in drug and device reviews to accelerate the deployment of advanced medical equipment for cancer treatment [2] Drug and Device Approvals - Kehua Bio announced that its subsidiaries received medical device registration certificates for various in vitro diagnostic reagents, which will enrich the company's product line and positively impact business development, although future revenue impact remains uncertain [4] - Heng Rui Medicine reported that its subsidiaries received clinical trial approval notices for SHR-7787 injection and Abedolizumab injection, with plans to conduct clinical trials soon [5] Capital Market Activities - Hite Bio plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its competitiveness and utilize international capital markets for diversified financing [7] - Hualan Biological announced a 450 million RMB capital increase for its wholly-owned subsidiary, Lingqing Intelligent, to strengthen its capabilities in AI drug development and commercialization [8] - Aibo Medical intends to acquire at least 51% of Demai Medical's shares to gain control, aiming to expand into the sports medicine sector [9][10] Industry Events - The fourth batch of traditional Chinese medicine centralized procurement is expected to progress, with significant price reductions observed in previous batches, indicating a shift in the competitive landscape of the industry [12] - Junshi Bioscience established a new technology company in Shanghai with a registered capital of 500 million RMB, focusing on various consulting and import-export services [13] Shareholder Movements - Jiukang Bio reported that a shareholder reduced their holdings by 1.4543 million shares, representing 0.248% of the total share capital, during a period when the stock price increased by 1.95% [15]

Core Viewpoint - The company is focusing on accelerating the development of innovative drugs through its strong oncology research team and strategic global clinical development capabilities, aiming to become a leading innovator in cancer treatment [1]. Group 1: Company Strategy and Development - The company has one of the largest oncology clinical research teams in the industry and is leveraging this to enhance its innovative drug offerings [1]. - In the past 18 months, the company has advanced 15 new molecular entities into clinical development, covering various treatment modalities [1]. - From 2026 onwards, the company expects to introduce 8 to 10 new molecular entities into clinical development each year, signaling a new wave of innovation [1]. Group 2: Pipeline and Future Prospects - Several products in the company's pipeline, including CDK4 inhibitors, B7-H4 ADC, PRMT5 inhibitors, GPC3x41BB bispecific antibodies, and CEA ADC, are expected to enter late-stage clinical development by 2026 [1]. - The company is committed to building a sustainable competitive advantage and will continue to invest in a rich and innovative R&D pipeline [1]. - The company aims to actively seek and execute business expansion opportunities that create long-term value [1].

（文章来源：每日经济新闻） 每经AI快讯，天眼查工商信息显示，近日，上海君亦乐生物科技有限公司成立，注册资本5亿元人民 币，经营范围包括货物进出口、技术进出口、信息咨询服务等。股东信息显示，该公司由君实生物全资 持股。 ...

Group 1 - The core viewpoint of the news highlights the growth of the biomedical sector in China's STAR Market, with the STAR Market Biomedical Index rising by 0.29% and specific stocks like Tianzhihang increasing by 14.64% [1] - The National Healthcare Security Administration has released a guideline for pricing surgical and treatment auxiliary medical services, establishing a fee framework for innovative technologies such as surgical robots and remote surgeries, promoting a coefficient-based charging model linked to robotic assistance [1] - Guohai Securities points out that artificial intelligence is accelerating the empowerment of the entire pharmaceutical industry chain, with NVIDIA and Eli Lilly announcing a joint AI innovation lab, investing up to $1 billion over five years to explore AI applications in drug discovery, development, and manufacturing [1] Group 2 - As of December 31, 2025, the top ten weighted stocks in the STAR Market Biomedical Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 48.85% of the index [1] - The STAR Market Medical ETF by Harvest (588700) closely tracks the STAR Market Biomedical Index, providing an easy investment opportunity in the biomedical sector for investors without stock accounts through the Harvest Medical ETF linked fund (021061) [2]